Bayer Expands Levitra Marketing Rights Outside U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer purchases GlaxoSmithKline's co-promotion rights to the erectile dysfunction agent "in most major markets outside the U.S.," nearly four months after selling the U.S. marketing rights to its primary care products, including Levitra, to Schering-Plough.
You may also be interested in...
Bayer Spring Investor Conference March 16 Will Stress 2004 Financial Upturn
Restructuring is seen as a key factor in Bayer's improved performance. Its U.S. oncology business and ex-U.S. Levitra promotion are among likely topics for updates at the investor meeting.
Bayer Spring Investor Conference March 16 Will Stress 2004 Financial Upturn
Restructuring is seen as a key factor in Bayer's improved performance. Its U.S. oncology business and ex-U.S. Levitra promotion are among likely topics for updates at the investor meeting.
Schering-Plough Adds Levitra To Product Portfolio Through Deal With Bayer
Bayer abandons primary care market in U.S. and will cut 1,800 sales positions. Schering-Plough will take over marketing of Avelox and Cipro as well as Bayer's portion of Levitra co-promotion efforts.